加速高龄及体弱人群新冠疫苗全覆盖、夯实防疫工作的根基 (倡议书)

2022-04-12 网络 网络

信息来自:广州医科大学教授、呼吸疾病国家重点实验室首席研究员周荣博士

信息来自:广州医科大学教授、呼吸疾病国家重点实验室首席研究员周荣博士

随着国外的不断放开管控,欧美等国家以前期大量高龄或体弱人群的重症和死亡,加上疫苗的普及接种,换来了社会的群体性免疫基础。国外管控的放开,虽然不断有新的冠状病毒变异株出现,但由于前期疫苗接种或感染形成的免疫对抗力和免疫记忆力,绝大多数新感染者症状轻微、甚至无症状。过去两年多来,我国以生命至上引导疫情防控工作,取得了全球瞩目的成就,发病率、重症率、死亡人数都是全世界最低,但存在高新冠新重症率和死亡率的年高或有较严重基础病人群仍有较多未接种新冠疫苗的问题。

就新冠病毒变异株的流行态势和国外流行情况看来,新冠病毒疫苗不能隔止病毒感染,但是可以很有效地降低重症率和死亡率。所以,我国有序放开管控、逐步恢复正常生产和生活的前提基础就是迅速想方设法、刻不容缓、千方百计让未接种过新冠疫苗的 60 岁以上的高龄和有基础病的人群迅速完成接种工作,力争都完成第 4 针。

加强科学的新冠防疫宣传教育工作,尽快完成新冠疫苗接种工作。特倡议如下:

一是反复强调疫苗接种效果。疫苗接种虽然不能阻断新冠病毒新的变异株的感染,但能有效减少重症率和病死率。

二是加强舆情引导。一些感染新冠会危害多器官、会产生严重后遗症的各类研究及报道,因为这些结论或推测只是极少数个案,发生机理并不明确,多与个体身体状况或诊治过程有关,不具备普遍性,要合理引导群众科学理解及对待。

三是强调老年和体弱者等重点群体是疫苗接种重点对象。选择能在老年或有基础病的人群中迅速有效产生体液和细胞免疫反应的合适疫苗品种推广接种,迅速建立起重点人群的基础免疫力。

四是倡议领导、明星公开自己疫苗接种现场照片、录相等相关佐证材料,发挥积极影响力、推动疫苗接种的普及。

五是制订多层次政策,明确因未接种新冠疫苗而感染上新冠病毒需要救治者一律自费。

六是目前有新的零星疫情发生时,在一定的地理空间内进行管控的同时,在管控区内进一步加强有效疫苗的接种率、 特别是年长或体弱者。及时总结分析,以供借鉴。

根据呼吸道自限性病毒传染病的发生和发展规律,新冠已接近于演变成一种将在人类中持续传播下去的、可自愈的、会不断变异并反复感染的、但对前期已感染过或通过疫苗接种形成基础免疫能力个体症状渐趋轻微的、可与人及多种动物共存的病毒种类。应对这类病毒最有效的方式就是在形成较理想的群体性基础免疫力的时间点,尽可能全面放开。对新冠而言,这个时间点是在接种疫苗后,特别是年长体弱者等重点群体完成全程疫苗接种后的 0-12 个月内。这种群体性基础免疫力可能无法绝对地阻断感染,但绝大部分已感染过或接种过特异疫苗的个体都具备快速应对清除变种新病毒、并加自身强免疫的能力。即使有新的变异病毒株,只要有一定的交叉保护作用就不可怕,接触后可快速唤醒已经具有的免疫记忆,限制病毒侵入体内的感染范围,并将之快速清除。病毒毒力“超弱株”奥密克戎,是在群体不断地被病毒变异株反复感染后形成,几乎所有打过疫苗或感染过新冠病毒的个体对该种病毒都有特异性基础免疫力。我们应该高效抓住我国当前以不惜牺牲巨大经济损失换来的新冠防疫尚在的黄金时间段,迅速完成前期因高龄及有基础疾病未完成疫苗接种的全覆盖,否则,这个特别重要的易感人群始终存在那里,若要继续坚持生命至上、最大限度的减少重症和死亡发生,那就只能继续坚持以封控为核心的严格防控策略,正常放开难度大。

不打疫苗,首先是将自己的生命置于危险境地,其次你可能在感染后成为一个传染源、病毒库,给他人造成威胁,拖了全人类的后腿。 坚持以生命至上、最大限度保障人民生命健康的原则,不仅是政府的事情,更是我们每一个公民或人类每一个个体的事情,让我们全民皆兵、拿起我们自身免疫力这个最有力的武器,共同战胜新冠及其他各类传染病吧!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2066298, encodeId=7d4120662986b, content=<a href='/topic/show?id=978c2966046' target=_blank style='color:#2F92EE;'>#全覆盖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29660, encryptionId=978c2966046, topicName=全覆盖)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Sun Dec 25 20:16:38 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402624, encodeId=08fb140262442, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Wed Apr 13 23:16:38 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416134, encodeId=c92d141613496, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Wed Apr 13 23:16:38 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210472, encodeId=f44c12104e250, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 08:58:23 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2066298, encodeId=7d4120662986b, content=<a href='/topic/show?id=978c2966046' target=_blank style='color:#2F92EE;'>#全覆盖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29660, encryptionId=978c2966046, topicName=全覆盖)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Sun Dec 25 20:16:38 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402624, encodeId=08fb140262442, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Wed Apr 13 23:16:38 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416134, encodeId=c92d141613496, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Wed Apr 13 23:16:38 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210472, encodeId=f44c12104e250, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 08:58:23 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2066298, encodeId=7d4120662986b, content=<a href='/topic/show?id=978c2966046' target=_blank style='color:#2F92EE;'>#全覆盖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29660, encryptionId=978c2966046, topicName=全覆盖)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Sun Dec 25 20:16:38 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402624, encodeId=08fb140262442, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Wed Apr 13 23:16:38 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416134, encodeId=c92d141613496, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Wed Apr 13 23:16:38 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210472, encodeId=f44c12104e250, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 08:58:23 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2022-04-13 xlysu
  4. [GetPortalCommentsPageByObjectIdResponse(id=2066298, encodeId=7d4120662986b, content=<a href='/topic/show?id=978c2966046' target=_blank style='color:#2F92EE;'>#全覆盖#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29660, encryptionId=978c2966046, topicName=全覆盖)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/L2dMhrxjvSWuPWKZZP1I83Rw21EWia7LVTYJibLQkb4oTibrYLwhnAXntTBWR3FruIzKfNMiaBwhYV0AKNmiaNxfialg/132, createdBy=6ea92500119, createdName=ms9608593228839890, createdTime=Sun Dec 25 20:16:38 CST 2022, time=2022-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402624, encodeId=08fb140262442, content=<a href='/topic/show?id=546f9e45197' target=_blank style='color:#2F92EE;'>#防疫#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97451, encryptionId=546f9e45197, topicName=防疫)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf7e2418349, createdName=zhangying8789, createdTime=Wed Apr 13 23:16:38 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1416134, encodeId=c92d141613496, content=<a href='/topic/show?id=99fb1028231b' target=_blank style='color:#2F92EE;'>#高龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102823, encryptionId=99fb1028231b, topicName=高龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=307c3130149, createdName=xlysu, createdTime=Wed Apr 13 23:16:38 CST 2022, time=2022-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1210472, encodeId=f44c12104e250, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=821f2227826, createdName=DR.Fu SIR, createdTime=Tue Apr 12 08:58:23 CST 2022, time=2022-04-12, status=1, ipAttribution=)]
    2022-04-12 DR.Fu SIR

    0

相关资讯

JEADV:1例斑块型银屑病患者在接种新冠疫苗后出现泛发性脓疱性银屑病红斑,并用risankizumab成功治疗

随着新冠肺炎疫苗的广泛使用,出现了几种皮肤不良反应,包括先前存在的皮肤病:1例斑块型银屑病患者在接种新冠疫苗后出现泛发性脓疱性银屑病红斑,并用risankizumab成功治疗

FDA:第四剂新冠疫苗获批!救命疫苗来了

最后切记,新冠病毒疫苗接种加上有效个人防护,仍是当前新冠肺炎疫情防控的重要手段。

丽珠V-01新冠疫苗针对老年及基础病人群保护力高达71.83%,已经生产成品约5000万剂

奥密克戎变异株传染性强、传播速度快。由于高龄、合并基础性疾病或者未接种疫苗而出现重症的风险增加,老年人成为高危人群。专家表示,老年人除了要做好个人防护之外,及时接种新冠疫苗尤为重要。

2022年3月28日简报:上海新增50+3450例;中国台湾疫情可能会失控;香港新增与死亡病例均快速回落,将推行家居新冠疫苗接种计划

截至北京时间2022年3月28日7时01分,Worldometers世界实时统计数据显示,全球累计确诊新冠肺炎(COVID-19)病例超过4亿8185万例,新增987,021例,达到481,856,7

Cell Discovery:二代重组蛋白新冠疫苗对多种变异株保护效果发布

新冠病毒变异株层出不穷,成为全球抗击新冠疫情关注的焦点,二代重组蛋白新冠疫苗应对新冠变异毒株的效果也因此备受关注。